1. Home
  2. MDV vs ZNTL Comparison

MDV vs ZNTL Comparison

Compare MDV & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modiv Industrial Inc. Class C

MDV

Modiv Industrial Inc. Class C

HOLD

Current Price

$15.07

Market Cap

159.4M

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.68

Market Cap

156.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDV
ZNTL
Founded
2015
2014
Country
United States
United States
Employees
12
N/A
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.4M
156.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
MDV
ZNTL
Price
$15.07
$2.68
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$19.00
$5.80
AVG Volume (30 Days)
63.3K
533.4K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
8.09%
N/A
EPS Growth
N/A
18.03
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.80
$1.01
52 Week High
$17.15
$3.95

Technical Indicators

Market Signals
Indicator
MDV
ZNTL
Relative Strength Index (RSI) 57.60 54.34
Support Level $14.08 $1.31
Resistance Level $15.56 $2.69
Average True Range (ATR) 0.40 0.21
MACD 0.08 0.00
Stochastic Oscillator 96.95 86.23

Price Performance

Historical Comparison
MDV
ZNTL

About MDV Modiv Industrial Inc. Class C

Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: